文献速递膀胱癌与上尿路尿路上皮癌

早期膀胱癌治愈定义与根治性治疗的系统综述

Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2025-10-30

该系统综述检索Embase和Medline,纳入83篇近5年真实世界研究,评估非肌层浸润性和肌层浸润性膀胱癌的治愈定义与疗效指标。结果显示中位至复发时间在NMIBC为10-89个月、MIBC为6-19个月,无复发生存为最常报告结局。结论认为5年无复发生存可能是早期膀胱癌合适的治愈定义。

要点

  • 5年无复发生存可能是早期膀胱癌合适的治愈定义。
  • NMIBC研究最常报告无复发生存,MIBC研究常报告总生存和无复发生存。
  • 中位至复发时间NMIBC为10-89个月,MIBC为6-19个月。

核心结论

  • 基于所综述证据,5年无复发生存似乎是早期膀胱癌合适的治愈定义。
  • 就该替代终点或其他替代指标达成共识,可支持临床试验设计并辅助临床与报销决策。

研究设计与样本

  • 系统文献综述,于2024年7月10日检索Embase和Medline。
  • 纳入近5年发表的真实世界证据研究,共83篇出版物。
  • 评估NMIBC和MIBC治疗的关键疗效结局:至复发时间、总生存和无复发生存。

主要发现

  • 7项NMIBC研究中位至复发时间范围为10至89个月。
  • 5项MIBC研究中位至复发时间范围为6至19个月。
  • 无复发生存在NMIBC出版物中为最常报告结局,在MIBC出版物中为第二常报告结局。
  • NMIBC研究常在1年、2年和5年报告总生存和无复发生存,MIBC研究常在3年和5年报告。

关键数值与推荐

  • 当前膀胱癌指南缺乏共识:哪些结局用于定义治愈、最佳测量时间点以及早期膀胱癌中哪些治疗可以根治性意图给予。
  • 5年无复发生存被提出作为早期膀胱癌治愈的合适定义。

临床怎么用

  • 临床决策中可考虑将5年无复发生存作为早期膀胱癌治愈的替代指标。
  • 该定义或可支持临床试验设计,并从医患和报销角度辅助医疗决策。

局限性

  • 仅纳入真实世界证据研究。
  • 纳入出版物限于近5年,采用5年截止。
  • 相关数据稀缺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Current guidelines on bladder cancer lack consensus on which outcomes should be used to define cure, the optimal time point for measurement, and which treatments can be given with curative intent in early bladder cancer. Our aim was to determine the optimal definition of cure by assessing cure definitions used in non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC) studies. METHODS: We conducted a systematic literature review via Embase and Medline on July 10, 2024, to identify real-world evidence (RWE) studies published within the previous 5 yr reporting key effectiveness outcomes (time to recurrence [TTR], overall survival [OS], and recurrence-free survival [RFS]) of NMIBC and MIBC treatments. KEY FINDINGS AND LIMITATIONS: Among 83 publications included in the review, median TTR ranged from 10 to 89 mo across seven NMIBC studies, and from 6 to 19 mo across five MIBC studies. RFS was the first and second most commonly reported outcome among the NMIBC and MIBC publications, respectively. OS and RFS were commonly reported at 1, 2, and 5 yr among NMIBC studies, and at 3 and 5 yr among MIBC studies. Limitations include the use of RWE only, the 5-yr cut-off for the publications included, and the scarcity of relevant data. CONCLUSIONS AND CLINICAL IMPLICATIONS: According to the evidence reviewed, 5-yr RFS appears to be a suitable definition of cure in early bladder cancer. Consensus on this or another surrogate outcome for measurement of cure could support the development of clinical trial designs and inform decision-making in health care from both clinician-patient and reimbursement perspectives.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Guerrero-Ramos F, Schwenke C, Pinto Á, et al. Systematic Review of the Definition of Cure and of Curative-intent Treatments in Early Bladder Cancer. Eur Urol Oncol. 2025. PMID: 41173778. doi:10.1016/j.euo.2025.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。